Pfizer’s Meningitis B Vaccine Trumenba Is CBER’s First ‘Breakthrough’ Approval
This article was originally published in The Pink Sheet Daily
FDA’s biologics center grants accelerated approval to the first U.S. vaccine targeting serogroup B meningococcal disease after a 4.5-month review; the vaccine is expected to come up for discussion, but not a vote, at CDC’s Advisory Committee on Immunization Practices meeting Oct. 30.
You may also be interested in...
Pfizer received support from emerging market sales in the third quarter that for now allows Ian Read to continue to search for bold stroke acquisitions or other plays.
Both companies have “breakthrough” therapy designations from FDA and both announced BLA filings on June 17, but Pfizer’s earlier completion of the rolling submission could give it an edge in the race to launch a meningitis B vaccine in the U.S.